Exploring the pathophysiology of Henoch-Schönlein purpura (HSP): A Comprehensive Review

[{“box”:0,”content”:”[if 992 equals=”Open Access”]n

n

n

n

Open Access

nn

n

n[/if 992]n

n

Year : May 27, 2024 at 3:52 pm | [if 1553 equals=””] Volume : [else] Volume :[/if 1553] | [if 424 equals=”Regular Issue”]Issue[/if 424][if 424 equals=”Special Issue”]Special Issue[/if 424] [if 424 equals=”Conference”][/if 424] : | Page : –

n

n

n

n

n

n

By

n

[foreach 286]n

n

n

Himanshu Jain, Kuljeet Kaur

n

    n t

  • n

n

n[/foreach]

n

n[if 2099 not_equal=”Yes”]n

    [foreach 286] [if 1175 not_equal=””]n t

  1. Lecturer, Research Scholar Department of Pharmaceutical Sciences, University Institute of pharmaceutical sciences and research, Baba Farid University of Health sciences, Department of Pharmaceutical Sciences, University Institute of pharmaceutical sciences and research, Baba Farid University of Health sciences Punjab, Punjab India, India

    2. n[/if 1175][/foreach]

n[/if 2099][if 2099 equals=”Yes”][/if 2099]n

n

Abstract

nBlood from tiny veins can leak into nearby tissues, causing purpura, a disorder marked by red spots or patches on the skin that may have an impact on the kidneys. Henoch-Schönlein purpura (HSP), are associated with vasculitis and inflammation of blood vessels. The range of renal conditions associated with purpura includes severe glomerulonephritis and mild proteinuria. For instance, immunological complex accumulation in the renal glomeruli of HSP patients might result in inflammation and renal injury. The pathophysiology of HSP is largely dependent on immunological pathways, including complement activation and immune complex deposition. Effective management of these renal symptoms depends on rapid identification and action. In addition to skin discoloration and renal involvement, purpura may present with other symptoms, including fatigue, joint pain, and mucosal bleeding. Though the precise etiology of HSP is unknown, it is thought to be related to an unbalanced immune system reaction that may be brought on by an infection or other circumstances. Treatment strategies depend on the underlying cause and may involve immunosuppressive therapy, plasma pheresis, or supportive care. For the most effective treatment for patients with HSP, a multidisciplinary strategy comprising gastroenterologists, nephrologists, and rheumatologists is recommended. Supportive treatment for gastrointestinal and renal disorders may include fluid replacement, pain relief, and, in certain situations, immunosuppressive medication. A long-term follow-up is necessary to evaluate renal function and keep an eye out for disease recurrence. The aim of this study is to give a thorough overview of HSP, including information on its pathophysiology, diagnosis, possibilities for treatment, and clinical signs and symptoms.

n

n

n

Keywords: Henoch-Schönlein purpura (HSP), renal disorder, IgA vasculitis, galactose-deficient IgA1, anti-endothelial cell antibodies, Nephritic

n[if 424 equals=”Regular Issue”][This article belongs to International Journal of Cell Biology and Cellular Functions(ijcbcf)]

n

[/if 424][if 424 equals=”Special Issue”][This article belongs to Special Issue under section in International Journal of Cell Biology and Cellular Functions(ijcbcf)][/if 424][if 424 equals=”Conference”]This article belongs to Conference [/if 424]

n

n

n

How to cite this article: Himanshu Jain, Kuljeet Kaur. Exploring the pathophysiology of Henoch-Schönlein purpura (HSP): A Comprehensive Review. International Journal of Cell Biology and Cellular Functions. May 27, 2024; ():-.

n

How to cite this URL: Himanshu Jain, Kuljeet Kaur. Exploring the pathophysiology of Henoch-Schönlein purpura (HSP): A Comprehensive Review. International Journal of Cell Biology and Cellular Functions. May 27, 2024; ():-. Available from: https://journals.stmjournals.com/ijcbcf/article=May 27, 2024/view=0

nn[if 992 equals=”Open Access”] Full Text PDF Download[/if 992] n[if 992 not_equal=”Open Access”]

[/if 992]n[if 992 not_equal=”Open Access”]

n

n

n[/if 992]nn[if 379 not_equal=””]n

Browse Figures

n

n

[foreach 379]n

n[/foreach]n

n

n

n[/if 379]n

n

References

n[if 1104 equals=””]n

  1. Jaszczura M, Dyga K, Bryłka A, Góra A, Machura E. IgA vasculitis, formerly known as Henoch-Schönlein purpura–the most common vasculitis in children. Pediatria Polska-Polish Journal of Paediatrics. 2018;93(4):336-42.
  2. Trnka P. H enoch–S chönlein purpura in children. Journal of paediatrics and child health. 2013 Dec;49(12):995-1003.
  3. Heineke MH, Ballering AV, Jamin A, Mkaddem SB, Monteiro RC, Van Egmond M. New insights in the pathogenesis of immunoglobulin A vasculitis (Henoch-Schönlein purpura). Autoimmunity reviews. 2017 Dec 1;16(12):1246-53.
  4. Trapani S, Micheli A, Grisolia F, Resti M, Chiappini E, Falcini F, De Martino M. Henoch Schonlein purpura in childhood: epidemiological and clinical analysis of 150 cases over a 5-year period and review of literature. InSeminars in arthritis and rheumatism 2005 Dec 1 (Vol. 35, No. 3, pp. 143-153). WB Saunders.
  5. Gardner-Medwin JM, Dolezalova P, Cummins C, Southwood TR. Incidence of Henoch-Schonlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. The Lancet. 2002 Oct 19;360(9341):1197-202.
  6. Calvino MC, Llorca J, Garcia-Porrua C, Fernandez-Iglesias JL, Rodriguez-Ledo P, Gonzalez-Gay MA. Henoch-Schönlein purpura in children from northwestern Spain: a 20-year epidemiologic and clinical study. Medicine. 2001 Sep 1;80(5):279-90.
  7. Watson L, Richardson AR, Holt RC, Jones CA, Beresford MW. Henoch schonlein purpura–a 5-year review and proposed pathway. PLoS One. 2012 Jan 3;7(1):e29512.
  8. Tizard EJ. Henoch-Schönlein purpura. Archives of disease in childhood. 1999 Apr 1;80(4):380-3.
  9. Prais D, Amir J, Nussinovitch M. Recurrent Henoch-Schönlein purpura in children. JCR: Journal of Clinical Rheumatology. 2007 Feb 1;13(1):25-8.
  10. Calvo-Río V, Hernández JL, Ortiz-Sanjuán F, Loricera J, Palmou-Fontana N, González-Vela MC, González-Lamuño D, González-López MA, Armesto S, Blanco R, González-Gay MA. Relapses in patients with Henoch–Schönlein purpura: analysis of 417 patients from a single center. Medicine. 2016 Jul 1;95(28):e4217.
  11. Lei WT, Tsai PL, Chu SH, Kao YH, Lin CY, Fang LC, Shyur SD, Lin YW, Wu SI. Incidence and risk factors for recurrent Henoch-Schönlein purpura in children from a 16-year nationwide database. Pediatric Rheumatology. 2018 Dec;16:1-0.
  12. Piram M, Mahr A. Epidemiology of immunoglobulin A vasculitis (Henoch–Schönlein): current state of knowledge. Current opinion in rheumatology. 2013 Mar 1;25(2):171-8.
  13. Saulsbury FT. Henoch–Schönlein purpura. Current opinion in rheumatology. 2010 Sep 1;22(5):598-602.
  14. Butt G, Anees M, Rana M. Frequency of renal manifestations in patients of Henoch-Schonlein purpura. Journal of Pakistan Association of Dermatologists. 2021 Aug 6;31(2):146-52.
  15. Hetland LE, Susrud KS, Lindahl KH, Bygum A. Henoch-Schönlein purpura: a literature review. Acta dermato-venereologica. 2017 Aug 7;97(10):1160-6.
  16. Sag E, Arici ZS, Ozen S. IgA vasculitis (Henoch–Schönlein purpura) in children. Expert Opinion on Orphan Drugs. 2017 May 4;5(5):405-10.
  17. Abbas S, Geetha S, Deepthi RV, Kamar J, Uthup S. Clinical profile and outcome of Henoch Schonlein purpura in a tertiary care hospital in South India. International Journal of Contemporary Pediatrics. 2017 May;4(3):822-6.
  18. Ozen S, Marks SD, Brogan P, Groot N, de Graeff N, Avcin T, Bader-Meunier B, Dolezalova P, Feldman BM, Kone-Paut I, Lahdenne P. European consensus-based recommendations for diagnosis and treatment of immunoglobulin A vasculitis—the SHARE initiative. Rheumatology. 2019 Sep 1;58(9):1607-16.
  19. Audemard-Verger A, Pillebout E, Guillevin L, Thervet E, Terrier B. IgA vasculitis (Henoch–Shönlein purpura) in adults: Diagnostic and therapeutic aspects. Autoimmunity reviews. 2015 Jul 1;14(7):579-85.
  20. Calvo-Río V, Loricera J, Mata C, Martín L, Ortiz-Sanjuán F, Alvarez L, González-Vela MC, González-Lamuño D, Rueda-Gotor J, Fernández-Llaca H, González-López MA. Henoch-Schönlein purpura in northern Spain: clinical spectrum of the disease in 417 patients from a single center. Medicine. 2014 Mar 1;93(2):106-13.
  21. Alharthi AA. Henoch-Schonlein purpura in Saudi Arabia: A retrospective study of 27 children in Taif region. Current Pediatric Research. 2016 Jul 1;20(1-2):126-31.
  22. Watson L, Richardson AR, Holt RC, Jones CA, Beresford MW. Henoch schonlein purpura–a 5-year review and proposed pathway. PLoS One. 2012 Jan 3;7(1):e29512.
  23. Zhao YL, Liu ZJ, Bai XM, Wang YC, Li GH, Yan XY. Obesity increases the risk of renal involvement in children with Henoch–Schönlein purpura. European journal of pediatrics. 2015 Oct;174:1357-63.
  24. Narchi H. Risk of long term renal impairment and duration of follow up recommended for Henoch-Schönlein purpura with normal or minimal urinary findings: a systematic review. Archives of disease in childhood. 2005 Sep 1;90(9):916-20.
  25. Modi S, Mohan M, Jennings A. Acute scrotal swelling in Henoch-Schonlein purpura: case report and review of the literature. Urology Case Reports. 2016 May 1;6:9-11.
  26. Dos Santos D, Langer FW, Dos Santos T, Rafael Tronco Alves G, Feiten M, Teixeira de Paula Neto W. Posterior reversible encephalopathy syndrome as a complication of Henoch–Schönlein purpura in a seven-year-old girl. Scottish Medical Journal. 2017 Feb;62(1):34-7.
  27. Hwang JJ, Ahn J, Kim KP, Choi HI, Choi JY, Song R, Lee YA, Lee SH, Hong SJ, Yang HI. Henoch-Schönlein purpura with muscle involvement, presenting as myositis. JCR: Journal of Clinical Rheumatology. 2017 Jan 1;23(1):60-2.
  28. Michas G, Grigoriou K, Syrigos D, Alexopoulos N, Evdoridis C, Trikas A. A rare cause of myocarditis resulting in acute heart failure in the setting of Henoch-Schönlein purpura. Hellenic Journal of Cardiology: HJC= Hellenike Kardiologike Epitheorese. 2017 May 18;58(6):439-42.
  29. Woof JM, Kerr MA. The function of immunoglobulin A in immunity. The Journal of Pathology: A Journal of the Pathological Society of Great Britain and Ireland. 2006 Jan;208(2):270-82.
  30. Crago SS, Kutteh WH, Moro I, Allansmith MR, Radl J, Haaijman JJ, Mestecky J. Distribution of IgA1-, IgA2-, and J chain-containing cells in human tissues. J Immunol. 1984 Jan 1;132(1):16-8.
  31. Roos A, Bouwman LH, van Gijlswijk-Janssen DJ, Faber-Krol MC, Stahl GL, Daha MR. Human IgA activates the complement system via the mannan-binding lectin pathway. The Journal of Immunology. 2001 Sep 1;167(5):2861-8.
  32. Hiemstra PS, Gorter A, Stuurman ME, Van Es LA, Daha MR. Activation of the alternative pathway of complement by human serum IgA. European journal of immunology. 1987;17(3):321-6.
  33. Aleyd E, Heineke MH, van Egmond M. The era of the immunoglobulin A Fc receptor Fcα RI; its function and potential as target in disease. Immunological reviews. 2015 Nov;268(1):123-38.
  34. Blank U, Launay P, Benhamou M, Monteiro RC. Inhibitory ITAMs as novel regulators of immunity. Immunological reviews. 2009 Nov;232(1):59-71.
  35. Pasquier B, Launay P, Kanamaru Y, Moura IC, Pfirsch S, Ruffié C, Hénin D, Benhamou M, Pretolani M, Blank U, Monteiro RC. Identification of FcαRI as an inhibitory receptor that controls inflammation: dual role of FcRγ ITAM. Immunity. 2005 Jan 1;22(1):31-42.
  36. Mkaddem SB, Rossato E, Heming N, Monteiro RC. Anti-inflammatory role of the IgA Fc receptor (CD89): from autoimmunity to therapeutic perspectives. Autoimmunity reviews. 2013 Apr 1;12(6):666-9.
  37. Heineke MH, van Egmond M. Immunoglobulin A: magic bullet or Trojan horse?. European journal of clinical investigation. 2017 Feb;47(2):184-92.
  38. Aleyd E, van Hout MW, Ganzevles SH, Hoeben KA, Everts V, Bakema JE, van Egmond M. IgA enhances NETosis and release of neutrophil extracellular traps by polymorphonuclear cells via Fcα receptor I. The Journal of Immunology. 2014 Mar 1;192(5):2374-83.
  39. van der Steen LP, Bakema JE, Sesarman A, Florea F, Tuk CW, Kirtschig G, Hage JJ, Sitaru C, van Egmond M. Blocking Fcα receptor I on granulocytes prevents tissue damage induced by IgA autoantibodies. The Journal of Immunology. 2012 Aug 15;189(4):1594-601.
  40. Jennewein MF, Alter G. The immunoregulatory roles of antibody glycosylation. Trends in immunology. 2017 May 1;38(5):358-72.
  41. Launay P, Grossetête B, Arcos-Fajardo M, Gaudin E, Torres SP, Beaudoin L, Patey-Mariaud de Serre N, Lehuen A, Monteiro RC. Fcα Receptor (Cd89) Mediates the Development of Immunoglobulin a (Iga) Nephropathy (Berger’s Disease) Evidence for Pathogenic Soluble Receptor–Iga Complexes in Patients and Cd89 Transgenic Mice. The Journal of experimental medicine. 2000 Jun 5;191(11):1999-2010.
  42. Tissandié E, Morelle W, Berthelot L, Vrtovsnik F, Daugas E, Walker F, Lebrec D, Trawalé JM, Francoz C, Durand F, Moura IC. Both IgA nephropathy and alcoholic cirrhosis feature abnormally glycosylated IgA1 and soluble CD89–IgA and IgG–IgA complexes: common mechanisms for distinct diseases. Kidney international. 2011 Dec 2;80(12):1352-63.
  43. Vuong MT, Hahn-Zoric M, Lundberg S, Gunnarsson I, Van Kooten C, Wramner L, Seddighzadeh M, Fernström A, Hanson LÅ, Do LT, Jacobson SH. Association of soluble CD89 levels with disease progression but not susceptibility in IgA nephropathy. Kidney international. 2010 Dec 2;78(12):1281-7.
  44. Wilkinson A. Early recognition and treatment of Henoch-Schönlein purpura in children. Nursing Children and Young People. 2019 Sep 5;31(5).
  45. Watanabe T. Henoch-Schönlein purpura following influenza vaccinations during the pandemic of influenza A (H1N1). Pediatric Nephrology. 2011 May;26:795-8.
  46. Jariwala S, Vernon N, Shliozberg J. Henoch-Schönlein purpura after hepatitis A vaccination. Annals of Allergy, Asthma & Immunology. 2011 Aug 1;107(2):180-1.
  47. Mitsui H, Shibagaki N, Kawamura T, Matsue H, Shimada S. A clinical study of Henoch‐Schönlein Purpura associated with malignancy. Journal of the European Academy of Dermatology and Venereology. 2009 Apr;23(4):394-401.
  48. Blanco R, González-Gay MA, Ibáñez D, Alba C, Pérez de Llano LA. Henoch-Schönlein purpura as a clinical presentation of small cell lung cancer. Clinical and experimental rheumatology. 1997 Sep 1;15(5):545-7.
  49. Angelier AS, Petit L, Wynckel A, Vuiblet V, Birembaut P, Toubas O, Lebargy F, Deslee G. Schoenlein-Henoch purpura as a presentation of squamous cell bronchial carcinoma. Revue des Maladies Respiratoires. 2011 Feb 23;28(3):372-6.
  50. Nozato K, Morishima Y, Furuta J, Fujita J, Miyazaki K, Ogawa R, Kikuchi N, Sakamoto T, Hizawa N. A case of Henoch-Schönlein purpura which was difficult to distinguish from a skin rash associated with gefitinib. Nihon Kokyuki Gakkai Zasshi= the Journal of the Japanese Respiratory Society. 2010 Jul 1;48(7):529-34.
  51. Maritati F, Canzian A, Fenaroli P, Vaglio A. Adult-onset IgA vasculitis (Henoch-Schönlein): update on therapy. La Presse Médicale. 2020 Oct 1;49(3):104035.
  52. Kango SC, Palet JE, Bognin OB, Ouaimon D, Houndjahoue GF. Diagnostic Difficulties in A Case of Henoch-Schönlein Purpura at The Pediatric University Hospital Complex of Bangui. J Med Case Rep Case Series. 2022;3:19.
  53. Yang YH, Huang YH, Lin YL, Wang LC, Chuang YH, Yu HH, Lin YT, Chiang BL. Circulating IgA from acute stage of childhood Henoch-Schönlein purpura can enhance endothelial interleukin (IL)-8 production through MEK/ERK signalling pathway. Clinical & Experimental Immunology. 2006 May;144(2):247-53.
  54. Demir S, Candan C, Turhan P, Ergüven M. Henoch Schönlein Purpura/Ig A Vasculitis in Children and Risk Factors for Renal Involvement. Acta Medica. 2021 Aug 27;52(3):230-8.
  55. Szemenyei C, Hahn D. Prevention of nephritis in Henoch-Schönlein purpura. J Paediatr Child Health. 2015 Feb 1;51(2):236-9.
  56. Bogdanović R. Henoch‐Schönlein purpura nephritis in children: risk factors, prevention and treatment. Acta paediatrica. 2009 Dec;98(12):1882-9.
  57. Atkinson SR, Barker D. Seasonal distribution of Henoch-Schönlein purpura. Journal of Epidemiology & Community Health. 1976 Mar 1;30(1):22-5.
  58. Reamy BV, Servey JT, Williams PM. Henoch-Schönlein purpura (IgA vasculitis): rapid evidence review. American family physician. 2020 Aug 15;102(4):229-33.
  59. Lee DH, Eun-So LE, Hong J, Park KH, Pai KS. A Case of Henoch-Schönlein Purpura with Fulminant Complications and Its Long-term Outcome. Childhood Kidney Diseases. 2019 Oct 30;23(2):128-33.
  60. Chan H, Tang YL, Lv XH, Zhang GF, Wang M, Yang HP, Li Q. Risk factors associated with renal involvement in childhood Henoch-Schönlein purpura: a meta-analysis. PLoS One. 2016 Nov 30;11(11):e0167346.
  61. Gaia MJ, Capela M, Borges JP, Marques E, Ferreira G, Vinhas da Silva A. Henoch-Schönlein Purpura: What to expect. Port J Nephrol Hypert, Lisboa. 2019 Dec;33(4):212-6.
  62. Jelusic M, Sestan M, Cimaz R, Ozen S. Different histological classifications for Henoch-Schönlein purpura nephritis: which one should be used?. Pediatric Rheumatology. 2019 Dec;17:1-7.
  63. Liao CH, Tsai M, Yang YH, Chiang BL, Wang LC. Onset age is a risk factor for refractory pediatric IgA vasculitis: a retrospective cohort study. Pediatric Rheumatology. 2020 Dec;18:1-0.
  64. Wang X, Zhu Y, Gao L, Wei S, Zhen Y, Ma Q. Henoch-Schönlein purpura with joint involvement: Analysis of 71 cases. Pediatric Rheumatology. 2016 Dec;14:1-8.
  65. Dawood SA, Abodiah AM, Alqahtani SM, Shati AA, Alqahtani YA, Alshehri MA, Mahmood SE. Clinico-epidemiological profile and outcome of children with IgA vasculitis in Aseer Region, Southwestern Saudi Arabia. InHealthcare 2021 Dec 7 (Vol. 9, No. 12, p. 1694). MDPI.
  66. Pillebout E, Alberti C, Guillevin L, Ouslimani A, Thervet E, CESAR Study Group. Addition of cyclophosphamide to steroids provides no benefit compared with steroids alone in treating adult patients with severe Henoch Schönlein Purpura. Kidney international. 2010 Sep 1;78(5):495-502.
  67. Han DH. Clinical Analysis on 106 cases of $ Henoch-Sch {ddot {o}} nlein $ Purpura. The Journal of Internal Korean Medicine. 2007;28(3):570-85.
  68. Yang YH, Yu HH, Chiang BL. The diagnosis and classification of Henoch–Schönlein purpura: an updated review. Autoimmunity Reviews. 2014 Apr 1;13(4-5):355-8.
  69. Van de Perre E, Jones RB, Jayne DR. IgA vasculitis (Henoch–Schönlein purpura): refractory and relapsing disease course in the adult population. Clinical Kidney Journal. 2021 Aug 1;14(8):1953-60.
  70. Maritati F, Fenoglio R, Pillebout E, Emmi G, Urban ML, Rocco R, Nicastro M, Incerti M, Goldoni M, Trivioli G, Silvestri E. Brief Report: Rituximab for the Treatment of Adult‐Onset IgA Vasculitis (Henoch‐Schönlein). Arthritis & rheumatology. 2018 Jan;70(1):109-14.
  71. Audemard‐Verger A, Terrier B, Dechartres A, Chanal J, Amoura Z, Le Gouellec N, Cacoub P, Jourde‐Chiche N, Urbanski G, Augusto JF, Moulis G. Characteristics and management of IgA vasculitis (Henoch‐Schönlein) in adults: data From 260 patients included in a french multicenter retrospective survey. Arthritis & rheumatology. 2017 Sep;69(9):1862-70.
  72. Gohari A, Matsell DG, Mammen C, Goldman RD. Henoch-Schönlein purpura in children: Use of corticosteroids for prevention and treatment of renal disease. Canadian Family Physician. 2020 Dec 1;66(12):895-7.
  73. Butt G, Anees M, Rana M. Frequency of renal manifestations in patients of Henoch-Schonlein purpura. Journal of Pakistan Association of Dermatologists. 2021 Aug 6;31(2):146-52.

nn[/if 1104][if 1104 not_equal=””]n

    [foreach 1102]n t

  1. [if 1106 equals=””], [/if 1106][if 1106 not_equal=””],[/if 1106]

    2. n[/foreach]

n[/if 1104]

nn

nn[if 1114 equals=”Yes”]n

n[/if 1114]

n

n

[if 424 not_equal=””][else]Ahead of Print[/if 424] Subscription Review Article

n

n

[if 2146 equals=”Yes”][/if 2146][if 2146 not_equal=”Yes”][/if 2146]n

n

n

n

n

n

n

n

n

n

n

n

n

n

n

n

n

n

n

n

n[if 1748 not_equal=””]

[else]

[/if 1748]n

n

n

Volume
[if 424 equals=”Regular Issue”]Issue[/if 424][if 424 equals=”Special Issue”]Special Issue[/if 424] [if 424 equals=”Conference”][/if 424]
Received March 20, 2024
Accepted May 4, 2024
Published May 27, 2024

n

n

Views: 27

n

n

n

n function myFunction2() {n var x = document.getElementById(“browsefigure”);n if (x.style.display === “block”) {n x.style.display = “none”;n }n else { x.style.display = “Block”; }n }n document.querySelector(“.prevBtn”).addEventListener(“click”, () => {n changeSlides(-1);n });n document.querySelector(“.nextBtn”).addEventListener(“click”, () => {n changeSlides(1);n });n var slideIndex = 1;n showSlides(slideIndex);n function changeSlides(n) {n showSlides((slideIndex += n));n }n function currentSlide(n) {n showSlides((slideIndex = n));n }n function showSlides(n) {n var i;n var slides = document.getElementsByClassName(“Slide”);n var dots = document.getElementsByClassName(“Navdot”);n if (n > slides.length) { slideIndex = 1; }n if (n (item.style.display = “none”));n Array.from(dots).forEach(n item => (item.className = item.className.replace(” selected”, “”))n );n slides[slideIndex – 1].style.display = “block”;n dots[slideIndex – 1].className += ” selected”;n }n”}]